Market Cap 408.80M
Revenue (ttm) 0.00
Net Income (ttm) -66.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,939,800
Avg Vol 9,195,378
Day's Range N/A - N/A
Shares Out 180.09M
Stochastic %K 93%
Beta 0.90
Analysts Strong Sell
Price Target $10.00

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8099
Address:
80 Guest Street, Suite 601, Boston, United States
Heliosphere
Heliosphere Jul. 3 at 2:05 PM
$CMPX The post-hoc crossover data is doing the heavy lifting: crossover patients had a median OS of 12.8 months compared with 6.1 months in those who did not receive tovecimig after progression (HR 0.54, p=0.04), and PFS2 was 3.5 months vs 1.9 months (HR 0.36) — statistically significant, same direction, same drug. That’s the strongest biological argument that the OS signal is real but obscured.
0 · Reply
Heliosphere
Heliosphere Jul. 3 at 2:04 PM
$CMPX The ASCO Daily News KOL commentary piece A perspectives piece from the field of biliary tract cancer published in ASCO Daily News noted that “beyond first-line therapy, patients with biliary tract cancer without targetable alterations face a dearth of treatment options, representing an unmet need,” and characterized tovecimig as offering “hope in this disease space, demonstrating a manageable safety profile and promising efficacy, especially when combined with chemotherapy.”
0 · Reply
Heliosphere
Heliosphere Jul. 3 at 2:03 PM
$CMPX Juan Valle, MD — Chief Medical Officer, Cholangiocarcinoma Foundation (the most prominent named KOL) This is the most significant external expert commentary. Valle said: “Patients with advanced BTC have an urgent need for better treatment options. These results are a significant step forward and I anticipate that, if approved, it will meaningfully change the way physicians care for these patients. I also applaud Compass for putting patients first in the design of this study by allowing patients to crossover to receive treatment with tovecimig. These patients clearly benefited from this innovative therapy.” This is significant — Valle is a globally recognized biliary tract cancer KOL and his framing explicitly defends the crossover design as ethically justified, which is exactly the right counter-narrative to the OS miss.
0 · Reply
Brandonswest
Brandonswest Jul. 2 at 4:33 PM
$CMPX its trying!
0 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 2 at 3:26 PM
$NOK $KLAR $CMPX $CAVA not having the greatest morning but …
0 · Reply
TBROS1898
TBROS1898 Jul. 2 at 2:14 PM
$CMPX fly birdie fly
0 · Reply
GangsterX
GangsterX Jul. 2 at 5:54 AM
$FATE $CMPX $CNTX $PEPG $PMVP Never sell baby
1 · Reply
Brandonswest
Brandonswest Jul. 2 at 12:43 AM
0 · Reply
Heliosphere
Heliosphere Jul. 1 at 7:22 PM
0 · Reply
TooMuchFinesse
TooMuchFinesse Jun. 30 at 6:01 PM
$CMPX Like I said…
0 · Reply
Latest News on CMPX
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)

2026-05-05T12:13:40.000Z - 2 months ago

Compass Therapeutics reports Q1 EPS (10c), consensus (10c)


Compass Therapeutics Earnings release: Q1 2026

May 5, 2026, 7:30 AM EDT - 2 months ago

Compass Therapeutics Earnings release: Q1 2026


Compass Therapeutics Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 2 months ago

Compass Therapeutics Quarterly report: Q1 2026


Compass Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Proxy statement: Proxy filing


Compass Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Proxy statement: Proxy filing


Compass Therapeutics Transcript: Study update

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Transcript: Study update


Compass Therapeutics Press release: Study update

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Press release: Study update


Compass Therapeutics Slides: Study update

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Slides: Study update


Compass Therapeutics reports Q4 EPS (9c), consensus (9c)

2026-03-05T12:38:02.000Z - 4 months ago

Compass Therapeutics reports Q4 EPS (9c), consensus (9c)


Compass Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 7:30 AM EST - 4 months ago

Compass Therapeutics Earnings release: Q4 2025


Compass Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:30 AM EST - 4 months ago

Compass Therapeutics Annual report: Q4 2025


Compass Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:30 AM EST - 4 months ago

Compass Therapeutics Annual report: Q4 2025


Compass Therapeutics Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 4 months ago

Compass Therapeutics Slides: Corporate presentation


Compass Therapeutics initiated with a Buy at Craig-Hallum

2026-02-13T13:15:26.000Z - 5 months ago

Compass Therapeutics initiated with a Buy at Craig-Hallum


Compass Therapeutics Slides: Corporate presentation

Jan 7, 2026, 7:00 AM EST - 6 months ago

Compass Therapeutics Slides: Corporate presentation


Compass Therapeutics provides corporate update

2026-01-06T13:36:59.000Z - 6 months ago

Compass Therapeutics provides corporate update


Compass Therapeutics Provides Corporate Update

Jan 6, 2026, 8:00 AM EST - 6 months ago

Compass Therapeutics Provides Corporate Update


Compass Therapeutics Announces Key Leadership Appointments

Jan 5, 2026, 8:00 AM EST - 6 months ago

Compass Therapeutics Announces Key Leadership Appointments


Compass Therapeutics files $400M mixed securities shelf

2025-12-30T21:10:54.000Z - 6 months ago

Compass Therapeutics files $400M mixed securities shelf


Compass Therapeutics Registration statement: Registration Filing

Dec 30, 2025, 7:00 AM EST - 6 months ago

Compass Therapeutics Registration statement: Registration Filing


Compass Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 8 months ago

Compass Therapeutics Slides: Corporate Presentation


Compass Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 8 months ago

Compass Therapeutics Earnings release: Q3 2025


Compass Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 8 months ago

Compass Therapeutics Quarterly report: Q3 2025


Compass Therapeutics Announces Proposed Public Offering

Aug 12, 2025, 4:01 PM EDT - 11 months ago

Compass Therapeutics Announces Proposed Public Offering


Compass Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Compass Therapeutics Earnings Call Transcript: Q2 2025


Compass Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Compass Therapeutics Quarterly report: Q2 2025


Compass Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Compass Therapeutics Earnings release: Q2 2025


Compass Therapeutics Slides: Corporate Presentation

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Compass Therapeutics Slides: Corporate Presentation


Compass Therapeutics Slides: Investor Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Compass Therapeutics Slides: Investor Presentation


Compass Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Earnings release: Q1 2025


Compass Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Quarterly report: Q1 2025


Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Transcript: Study Update

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Transcript: Study Update


Compass Therapeutics Slides: Study Update

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Slides: Study Update


Compass Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Annual report: Q4 2024


Compass Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Earnings release: Q4 2024


Compass Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compass Therapeutics Quarterly report: Q3 2024


Compass Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compass Therapeutics Earnings release: Q3 2024


Compass Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Quarterly report: Q2 2024


Compass Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Earnings release: Q2 2024


Compass Therapeutics Slides: Corporate Presentation

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Compass Therapeutics Slides: Corporate Presentation


Compass Therapeutics Proxy statement: Proxy Filing

May 29, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Announces CEO Transition

May 28, 2024, 4:10 PM EDT - 2 years ago

Compass Therapeutics Announces CEO Transition


Compass Therapeutics Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Compass Therapeutics Quarterly report: Q1 2024


Compass Therapeutics Earnings release: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Compass Therapeutics Earnings release: Q1 2024


Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Earnings release: Q4 2023


Compass Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Annual report: Q4 2023


Compass Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Compass Therapeutics Quarterly report: Q3 2023


Compass Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Compass Therapeutics Earnings release: Q3 2023


Compass Therapeutics Quarterly report: Q2 2023

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Compass Therapeutics Quarterly report: Q2 2023


Compass Therapeutics Earnings release: Q2 2023

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Compass Therapeutics Earnings release: Q2 2023


Heliosphere
Heliosphere Jul. 3 at 2:05 PM
$CMPX The post-hoc crossover data is doing the heavy lifting: crossover patients had a median OS of 12.8 months compared with 6.1 months in those who did not receive tovecimig after progression (HR 0.54, p=0.04), and PFS2 was 3.5 months vs 1.9 months (HR 0.36) — statistically significant, same direction, same drug. That’s the strongest biological argument that the OS signal is real but obscured.
0 · Reply
Heliosphere
Heliosphere Jul. 3 at 2:04 PM
$CMPX The ASCO Daily News KOL commentary piece A perspectives piece from the field of biliary tract cancer published in ASCO Daily News noted that “beyond first-line therapy, patients with biliary tract cancer without targetable alterations face a dearth of treatment options, representing an unmet need,” and characterized tovecimig as offering “hope in this disease space, demonstrating a manageable safety profile and promising efficacy, especially when combined with chemotherapy.”
0 · Reply
Heliosphere
Heliosphere Jul. 3 at 2:03 PM
$CMPX Juan Valle, MD — Chief Medical Officer, Cholangiocarcinoma Foundation (the most prominent named KOL) This is the most significant external expert commentary. Valle said: “Patients with advanced BTC have an urgent need for better treatment options. These results are a significant step forward and I anticipate that, if approved, it will meaningfully change the way physicians care for these patients. I also applaud Compass for putting patients first in the design of this study by allowing patients to crossover to receive treatment with tovecimig. These patients clearly benefited from this innovative therapy.” This is significant — Valle is a globally recognized biliary tract cancer KOL and his framing explicitly defends the crossover design as ethically justified, which is exactly the right counter-narrative to the OS miss.
0 · Reply
Brandonswest
Brandonswest Jul. 2 at 4:33 PM
$CMPX its trying!
0 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 2 at 3:26 PM
$NOK $KLAR $CMPX $CAVA not having the greatest morning but …
0 · Reply
TBROS1898
TBROS1898 Jul. 2 at 2:14 PM
$CMPX fly birdie fly
0 · Reply
GangsterX
GangsterX Jul. 2 at 5:54 AM
$FATE $CMPX $CNTX $PEPG $PMVP Never sell baby
1 · Reply
Brandonswest
Brandonswest Jul. 2 at 12:43 AM
0 · Reply
Heliosphere
Heliosphere Jul. 1 at 7:22 PM
0 · Reply
TooMuchFinesse
TooMuchFinesse Jun. 30 at 6:01 PM
$CMPX Like I said…
0 · Reply
FuhqAgentOrange
FuhqAgentOrange Jun. 30 at 5:10 PM
$CMPX 👀
0 · Reply
Heliosphere
Heliosphere Jun. 30 at 4:46 PM
0 · Reply
OnlyFibs
OnlyFibs Jun. 30 at 12:28 AM
$CMPX is trading at $2.08, and the technical setup in the chart analysis shows the stock coiling after the recent volatility. With short interest elevated at over 31% of the float, this name remains highly sensitive to any positive clinical or investor-relation updates. Don't chase the noise—wait for a clean, volume-backed breakout above the current consolidation range to validate that the buyers are finally reclaiming control from the shorts. Discipline is your greatest asset here. 🧐⚡️ Bull Key Levels: A confirmed breakout above $2.20 sets the stage for a push toward $2.60+. 🐂🚀 Bear Key Levels: If $1.90 support gives way, the momentum resets firmly to the downside. 🐻📉 Take Profit Targets: $2.35 / $3.00 are my primary interest zones. 💰🎯 #hovdid #MarketPulse #Trading #CMPX #TechnicalSetup
3 · Reply
Heliosphere
Heliosphere Jun. 29 at 4:45 PM
0 · Reply
Heliosphere
Heliosphere Jun. 29 at 4:39 PM
$CMPX GREAT NEWS! The FDA accepted Replimune's (REPL) resubmitted BLA for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma, with a response expected by August 2026, according to RTTNews. BioPharma Dive described the acceptance as "the latest example of changing attitudes at the FDA." We have tracked RP1 since its second CRL earlier this year.
1 · Reply
Lexcol
Lexcol Jun. 29 at 2:37 PM
$OCGN Back to 2.30 $ Ocugen and $CMPX
0 · Reply
TooMuchFinesse
TooMuchFinesse Jun. 29 at 1:54 PM
$CMPX solid comparisons
0 · Reply
Heliosphere
Heliosphere Jun. 28 at 5:51 PM
$CMPX The GI oncology review division has an established institutional pattern in this exact tumor type of accepting PFS/ORR with crossover-confounded or absent OS — three times over. Ivosidenib is the most directly on-point: same drug class problem (antiangiogenic-adjacent mechanism in second-line BTC), same crossover-driven OS ambiguity, and FDA approved anyway after doing the adjusted analysis itself.
1 · Reply
Heliosphere
Heliosphere Jun. 28 at 5:50 PM
$CMPX Pemigatinib (Pemazyre) — no OS data needed at all • Approved on a single-arm trial with no comparator, based purely on ORR of 36% and duration of response of 9.1 months  — even less survival rigor than what tovecimig has, in the same disease, same line of therapy (second-line+ BTC). Futibatinib — same structure as pemigatinib, ORR of 42% with median duration of response of 9.7 months,  again single-arm, no OS requirement.
0 · Reply
Heliosphere
Heliosphere Jun. 28 at 5:50 PM
$CMPX Ivosidenib (Tibsovo) — the closest analog to tovecimig’s exact problem • Approved on PFS as primary endpoint in a trial allowing crossover, with PFS of 2.7 months vs 1.4 months, HR 0.37  — directionally strong PFS, but the OS picture had the exact crossover confound issue you’re dealing with. • Median OS was 10.8 vs 7.5 months with HR 0.79 (p=0.09) — not statistically significant — and this may have been impacted by crossover from placebo to treatment.  The placebo-arm OS got pulled up by crossover, just like COMPANION-002’s 54% crossover rate is suspected of doing. • FDA’s own final efficacy analysis, accounting for crossover, found placebo-arm OS was actually only 5.1 months  — meaning the FDA itself did the crossover-adjustment math and still approved. This is your single best precedent: same tumor type, same confound mechanism, same regulatory division, drug got through.
0 · Reply
TooMuchFinesse
TooMuchFinesse Jun. 28 at 12:42 PM
$CMPX Still not fully loaded, but almost 50% of the way there,
0 · Reply
TBROS1898
TBROS1898 Jun. 27 at 1:09 AM
$CMPX love how it keeps getting pegged to almost same price…normal hours usually reversed in after hours almost exactly majority of the time…odd?
1 · Reply